WO2011100477A3 - Antibodies and processes for preparing the same - Google Patents

Antibodies and processes for preparing the same Download PDF

Info

Publication number
WO2011100477A3
WO2011100477A3 PCT/US2011/024408 US2011024408W WO2011100477A3 WO 2011100477 A3 WO2011100477 A3 WO 2011100477A3 US 2011024408 W US2011024408 W US 2011024408W WO 2011100477 A3 WO2011100477 A3 WO 2011100477A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antibody producing
cells
organisms
processes
Prior art date
Application number
PCT/US2011/024408
Other languages
French (fr)
Other versions
WO2011100477A2 (en
Inventor
Yosef Refaeli
Brian Curtis Turner
Gregory Alan Bird
Original Assignee
Taiga Biotechnologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies, Inc. filed Critical Taiga Biotechnologies, Inc.
Publication of WO2011100477A2 publication Critical patent/WO2011100477A2/en
Publication of WO2011100477A3 publication Critical patent/WO2011100477A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
PCT/US2011/024408 2010-02-10 2011-02-10 Antibodies and processes for preparing the same WO2011100477A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30325610P 2010-02-10 2010-02-10
US61/303,256 2010-02-10

Publications (2)

Publication Number Publication Date
WO2011100477A2 WO2011100477A2 (en) 2011-08-18
WO2011100477A3 true WO2011100477A3 (en) 2012-04-12

Family

ID=44368440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/024408 WO2011100477A2 (en) 2010-02-10 2011-02-10 Antibodies and processes for preparing the same

Country Status (1)

Country Link
WO (1) WO2011100477A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626525C (en) 2005-10-18 2020-03-10 National Jewish Medical And Research Center Conditionally immortalized long-term stem cells and methods of making and using such cells
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP3339321B1 (en) 2008-08-28 2021-04-28 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
PT3424953T (en) 2011-06-06 2020-11-03 Novo Nordisk As Therapeutic antibodies
EP3868387A1 (en) 2012-07-20 2021-08-25 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
TW201922795A (en) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 Anti-MCAM antibodies and associated methods of use
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
CA3045017A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN115028739A (en) * 2017-08-03 2022-09-09 泰加生物工艺学公司 Methods and compositions for treating melanoma
TW202140553A (en) * 2020-01-13 2021-11-01 美商威特拉公司 Antibody molecules to c5ar1 and uses thereof
CN111732662B (en) * 2020-06-11 2023-09-15 军事科学院军事医学研究院军事兽医研究所 anti-H5N 1 virus entry antibody PTD-7B-mFc and application thereof
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062278A1 (en) * 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062278A1 (en) * 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
US20050244406A1 (en) * 2002-01-25 2005-11-03 Mackay Charles R Monoclonal antibodies against extracellular loops of c5ar

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUO, R. -F. ET AL.: "C5a, a Therapeutic target in sepsis.", RECENT PATENTS IN ANTI-INFECTIVE DRUG DISCOVERY, vol. 1, January 2006 (2006-01-01), pages 57 - 65 *
LEE, H. ET AL.: "Receptor for complement C5a. The importance of C5aR and the enigmatic role of C5L2.", IMMUNOLOGY AND CELL BIOLOGY, vol. 86, no. 2, 29 January 2008 (2008-01-29), pages 153 - 160 *
OPPERMANN, M. ET AL.: "Probing the human receptor for C5a anaphylatoxic with site-directed antibodies.", JOURNAL OF IMMUNOLOGY, vol. 151, no. 7, 1 October 1993 (1993-10-01), pages 3785 - 3794 *

Also Published As

Publication number Publication date
WO2011100477A2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2011100477A3 (en) Antibodies and processes for preparing the same
WO2009139930A3 (en) Antibodies and processes for preparing the same
WO2012097333A3 (en) Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2011113019A3 (en) Ctla4 proteins and their uses
MX2018000344A (en) Human cd3 binding antibody.
WO2012058588A3 (en) Novel egfr-binding molecules and immunoconjugates thereof
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
MX353144B (en) Heterodimeric antibody fc-containing proteins and methods for production thereof.
MX336682B (en) Antibodies against human csf-1r and uses thereof.
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2011056644A3 (en) Anti-glp-1r antibodies and their uses
WO2013040078A3 (en) Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
WO2015049517A3 (en) Animal models and therapeutic molecules
WO2011062997A3 (en) Human monoclonal antibodies to human nucleolin
MY181513A (en) Cell culture compositions and methods for polypeptide production
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EP2792236A3 (en) Animal models and therapeutic molecules
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2012032181A3 (en) Antibody derivatives
WO2011091350A3 (en) Methods & compositions for improving protein production
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
BR112015022529A2 (en) cell culture media and antibody production processes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742823

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11742823

Country of ref document: EP

Kind code of ref document: A2